Ipsen

Ipsen to relocate R&D activities to Cambridge, Mass.

Friday, September 27, 2013 10:28 AM

Ipsen plans to relocate its U.S. R&D operations to Cambridge, Mass., in 2014. This site will be key for innovation in targeted therapies across Ipsen's specialty areas as well as a center of excellence for peptides. The move also brings Ipsen closer to several key partners based in the Cambridge area, including prominent hospital centers, medical schools, biotech companies and universities, thereby further promoting and facilitating partnerships and open innovation.

More... »

Aesica appoints two business development managers

Monday, July 15, 2013 01:32 PM

Aesica, a global contract development and manufacturing organization (CDMO), has appointed Sven Thomas and David Ross business development managers. They will ensure potential customers are aware of how their manufacturing and development needs can be supported.

More... »

Ipsen, Harvard Medical School to collaborate

Monday, July 15, 2013 10:50 AM

Global pharmaceutical company Ipsen has initiated an R&D collaboration on novel engineered botulinum toxins with Harvard Medical School. Ipsen will fund Harvard research for at least three years to discover, evaluate and develop novel engineered recombinant botulinum toxins for the treatment of neurologic diseases.

More... »

Ipsen acquires Syntaxin

Monday, July 15, 2013 10:48 AM

Global pharmaceutical company Ipsen has acquired Syntaxin, a U.K.-based private life sciences company specialized in botulinum toxin engineering. Ipsen will pay $36.4 million up front, as well as up to $169 million in development and commercial milestones.

More... »

Ipsen, Inspiration enter into asset purchase agreement with Baxter on OBI-1

Friday, January 25, 2013 10:32 AM

Ipsen, a global specialty-driven pharmaceutical company, and Inspiration Biopharmaceuticals, a biopharmaceutical company focused on hemophilia, have entered into an Asset Purchase Agreement (APA) whereby healthcare company Baxter International will acquire worldwide rights to OBI-1, a recombinant porcine factor VIII (rpFVIII) in development for congenital hemophilia A with inhibitors and acquired hemophilia A, and Ipsen's industrial facility in Milford, Mass.

More... »

Oncodesign, KU Leuven, Ipsen collaborate on advancing drug discovery in Parkinson's disease

Wednesday, December 19, 2012 11:11 AM

Oncodesign, a biotech based in France, and the Laboratory for Neurobiology and Gene Therapy (LNGT) at the Katholieke Universiteit Leuven, have entered into a research collaboration to evaluate, along with a global specialty-driven pharmaceutical company Ipsen, Oncodesign’s compounds in multiple pharmacology models for Parkinson's disease.

More... »

Ipsen, Inspiration Biopharmaceuticals renegotiate strategic partnership

Tuesday, August 21, 2012 12:15 PM

Ipsen, a global specialty-driven pharmaceutical company, has renegotiated its 2010 strategic partnership agreement with Inspiration Biopharmaceuticals, a Cambridge, Mass.-based biopharmaceutical company focused on hemophilia, for the development and commercialization of Inspiration’s recombinant product portfolio.

More... »

Ipsen to relocate headquarters to New Jersey

Wednesday, April 25, 2012 10:59 AM

Ipsen, a global specialty-driven pharmaceutical company, has decided to open new commercial headquarters in Basking Ridge, N.J.

More... »

Ipsen expands presence in US market

Friday, December 16, 2011 07:48 AM

Ipsen's US-based subsidiary, Biomeasure, and its North American Operations group announced that it will further expand its commitment, investment and commercial presence in the US market. Ipsen will make a multi-million dollar capital investment in its Milford, MA research and development and technical operations facility, and will relocate US Operations headquarters from Brisbane, CA, to Bridgewater, NJ, in order to enhance the North American commercial organization.

More... »

Ipsen and Biomérieux partner in theranostics

Tuesday, March 1, 2011 01:22 PM

Two French companies have formed a global collaboration in theranostics. Ipsen and bioMérieux will focus on hormone-dependent cancers.

More... »